Profund Advisors LLC Trims Stake in Biogen Inc. $BIIB

Profund Advisors LLC lessened its holdings in Biogen Inc. (NASDAQ:BIIB) by 11.2% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 24,131 shares of the biotechnology company’s stock after selling 3,043 shares during the period. Profund Advisors LLC’s holdings in Biogen were worth $3,380,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors have also recently modified their holdings of the business. Elevation Point Wealth Partners LLC acquired a new position in shares of Biogen in the 2nd quarter worth approximately $25,000. Rothschild Investment LLC increased its holdings in Biogen by 64.7% in the 2nd quarter. Rothschild Investment LLC now owns 224 shares of the biotechnology company’s stock valued at $28,000 after purchasing an additional 88 shares during the last quarter. Concord Wealth Partners lifted its stake in Biogen by 100.0% during the second quarter. Concord Wealth Partners now owns 228 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 114 shares in the last quarter. True Wealth Design LLC boosted its position in shares of Biogen by 62.9% during the third quarter. True Wealth Design LLC now owns 233 shares of the biotechnology company’s stock worth $33,000 after buying an additional 90 shares during the period. Finally, NewSquare Capital LLC grew its position in Biogen by 134.6% in the 2nd quarter. NewSquare Capital LLC now owns 244 shares of the biotechnology company’s stock valued at $31,000 after acquiring an additional 140 shares in the last quarter. 87.93% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages recently weighed in on BIIB. Wolfe Research set a $231.00 target price on shares of Biogen in a research note on Monday. TD Cowen upped their price objective on Biogen from $175.00 to $215.00 and gave the stock a “buy” rating in a research report on Monday. The Goldman Sachs Group reiterated a “buy” rating on shares of Biogen in a research note on Monday. Mizuho boosted their target price on Biogen from $177.00 to $207.00 and gave the stock an “outperform” rating in a research note on Thursday, January 8th. Finally, Tudor Pickering set a $201.00 price target on Biogen in a report on Monday. Thirteen equities research analysts have rated the stock with a Buy rating and fifteen have issued a Hold rating to the company. According to MarketBeat, the company has an average rating of “Hold” and a consensus target price of $206.21.

Insiders Place Their Bets

In other news, insider Priya Singhal sold 748 shares of the stock in a transaction that occurred on Monday, February 2nd. The stock was sold at an average price of $179.30, for a total value of $134,116.40. Following the completion of the sale, the insider directly owned 6,271 shares of the company’s stock, valued at approximately $1,124,390.30. This represents a 10.66% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 0.18% of the company’s stock.

More Biogen News

Here are the key news stories impacting Biogen this week:

• Positive Sentiment: Q4 beat and upbeat guidance: Biogen reported fourth‑quarter and FY results ahead of expectations, prompting analysts to raise forecasts and price targets — a direct earnings-driven positive catalyst. Biogen Posts Q4 Beat, Analysts Raise Price Targets
• Positive Sentiment: Regulatory progress for Leqembi: A biologics license application for a subcutaneous formulation of Leqembi was designated for priority review — this could expand prescribing convenience and bolster long‑term franchise value. Biologics License Application for Subcutaneous LEQEMBI Designated for Priority Review
• Positive Sentiment: Geographic expansion: Reports that China fast‑tracked at‑home use of Leqembi add another potential growth market for the Alzheimer’s franchise. Biogen stock to pop again? China fast-tracks Leqembi
• Positive Sentiment: Big analyst upgrades: RBC raised its price target to $233 (Outperform) and HC Wainwright raised its target to $228 (Buy), both signalling double‑digit upside from current levels and reflecting confidence in Leqembi and cash‑flow prospects. RBC Raises Price Target on Biogen to $233
• Neutral Sentiment: Mixed/neutral analyst stances: Several shops (Citigroup, Piper Sandler, Wedbush, Truist) nudged price targets higher but kept Neutral/Hold ratings, leaving investor guidance mixed. Analyst Price Target Moves (Citigroup, Piper, Wedbush, Truist)
• Negative Sentiment: Franchise pressure and execution risk: Analysis points to MS‑franchise weakness and near‑term growth limits, which keep some analysts cautious despite the Alzheimer’s upside. Biogen FY25 Earnings: Stable EPS Amid MS Franchise Pressure

Biogen Price Performance

BIIB stock opened at $193.81 on Tuesday. The business has a 50 day moving average price of $177.26 and a 200 day moving average price of $157.48. The company has a quick ratio of 2.03, a current ratio of 2.68 and a debt-to-equity ratio of 0.34. The stock has a market cap of $28.43 billion, a price-to-earnings ratio of 22.00, a PEG ratio of 1.70 and a beta of 0.16. Biogen Inc. has a fifty-two week low of $110.04 and a fifty-two week high of $202.41.

Biogen (NASDAQ:BIIB) last released its quarterly earnings data on Friday, February 6th. The biotechnology company reported $1.99 earnings per share for the quarter, topping analysts’ consensus estimates of $1.61 by $0.38. Biogen had a net margin of 13.07% and a return on equity of 12.64%. The company had revenue of $2.28 billion for the quarter, compared to analysts’ expectations of $2.21 billion. During the same quarter last year, the company earned $3.44 earnings per share. The firm’s revenue for the quarter was down 7.2% on a year-over-year basis. Biogen has set its FY 2026 guidance at 15.250-16.250 EPS. Equities research analysts anticipate that Biogen Inc. will post 15.83 earnings per share for the current fiscal year.

Biogen Profile

Biogen Inc is a multinational biotechnology company focused on discovering, developing and delivering therapies for neurological and neurodegenerative diseases. Headquartered in Cambridge, Massachusetts, the company has a longstanding emphasis on neuroscience, with research and commercial activities spanning multiple therapeutic areas including multiple sclerosis, spinal muscular atrophy and Alzheimer’s disease. Biogen was founded in 1978 and has grown into a global biopharmaceutical firm with operations and commercial presence across North America, Europe, Japan and other international markets.

The company’s marketed portfolio has historically included several well-known therapies for multiple sclerosis such as Avonex, Tysabri and Tecfidera, and it has pursued treatments for rare neurological conditions and genetic neuromuscular disorders.